We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is it the Right Time to Hold TNDM Stock in Your Portfolio?
Read MoreHide Full Article
Key Takeaways
TNDM expands its product roadmap with Mobi tubeless and next-generation closed-loop technology.
TNDM's international sales rose 7% in second-quarter 2026, boosting direct-channel growth.
TNDM holds $456 million in cash and investments, but competition and supply constraints pose risks.
Tandem Diabetes Care, Inc. (TNDM - Free Report) is expanding its product roadmap with new integrations, broader device compatibility and next-generation closed-loop technology. The company's international expansion is driving sales growth and increasing direct-channel penetration across key markets. Strong cash reserves and the absence of short-term debt support its ongoing investments in growth. Yet, competitive pressure and supply constraints could weigh on growth.
In the past year, this Zacks Rank #3 (Hold) stock has risen 11.9% compared to the 7.6% growth of the industry. However, the S&P 500 composite has risen 21.2% during the same time period.
The renowned medical device company has a market capitalization of $1.10 billion. Tandem projects an estimated earnings growth rate of 74.4% for 2026, outpacing the industry’s 16.5% growth. TNDM’s earnings have surpassed estimates in each of the trailing four quarters, delivering an average surprise of 30.9%.
Let’s delve deeper.
Tailwinds for TNDM Stock
Product Roadmap Broadens Choice: Tandem’s platform strategy continues to add integrations and features that keep its installed base current while widening customer choice. In second-quarter 2026, the company submitted a 510(k) for Mobi tubeless and still targets a scaled launch in 2026, subject to FDA clearance. Dexcom G7 15-day compatibility is now available for Mobi and t:slim X2 in the United States, while t:slim X2 supports Abbott FreeStyle Libre 3 Plus in seven countries outside the United States. Tandem also received FDA approval of an IDE for its AIDANET fully closed-loop program and plans to begin a pivotal study later in 2026. These milestones extend the roadmap beyond current durable pumps and broaden potential competitive conversion opportunities.
Image Source: Zacks Investment Research
International Expansion Supports Mix: International markets remain less penetrated than the United States and provide room for adoption as Tandem expands direct commercialization. In second-quarter 2026, international sales rose 7% year over year to $75.3 million and pump shipments increased 19% to about 11,000. Direct-channel sales reached about 13% of international revenues compared with 4% a year earlier, despite roughly $3 million of distributor inventory buybacks and destocking tied to market transitions. Tandem launched direct operations in the United Kingdom, Switzerland and Austria, with France planned for the fourth quarter of 2026. The company also plans to introduce Mobi in more than 10 countries by year-end, adding another route to grow pump starts and recurring supplies.
Liquidity Supports Execution: Tandem ended second-quarter 2026 with $456 million of cash, cash equivalents and short-term investments and further reinforced its balance sheet by closing a 0.00% convertible debt offering due 2032. The company had no short-term debt at the end of the quarter. Net cash used in operating activities was $23.6 million for the first half of 2026, modestly better than $27.8 million a year earlier despite investment in commercial infrastructure and product development.
Challenges for TNDM Stock
Tough Competitive Pressure: Tandem operates in a fast-changing insulin delivery market where rivals can use broader distribution, pricing incentives and new device features to influence payer and patient choices. The company also states that adoption of GLP-1 drugs has likely weighed on the insulin therapy market since 2023. Its response depends on maintaining differentiation through Control-IQ+, sensor compatibility and new form factors. Tandem submitted Mobi tubeless for FDA review in second-quarter 2026, but clearance and launch execution are still required before it can participate directly in the faster-growing tubeless segment identified by management.
Reliance on Pump Platform Execution: Tandem depends on pump placements to expand its installed base and drive recurring supply demand, leaving results sensitive to product launches and component availability. In second-quarter 2026, the company shipped about 33,000 pumps worldwide, while a key infusion set supplier constrained supply sales and inventory. Management believes the second quarter carried the greatest impact, but the 10-Q states inventory constraints are expected to persist through 2026. AutoSoft Plus is intended to reduce demand for allocated infusion-set SKUs, and SteadiSet is planned for the first half of 2027.
TNDM Stock Consensus Trend
The Zacks Consensus Estimate for Tandem’s 2026 loss per share currently stands at 66 cents, indicating a year-over-year improvement of 74.4%.
The same for 2026 revenues is pegged at $1.07 billion. This suggests a 5.7% increase from the year-ago reported number.
Phibro Animal Health has an earnings yield of 9.3% compared with the industry’s 2.7% yield. Shares of the company have risen 2.8% against the industry’s 28.9% decline. PAHC’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 18.4%.
Abbott, carrying a Zacks Rank #2 (Buy), has an earnings yield of 5.6% compared with the industry’s 2.6% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 0.8%. ABT’s shares have plunged 25.7% compared with the industry’s 28.9% decline over the past year.
Globus Medical, carrying a Zacks Rank #2, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 29.6% compared with the industry’s 7.6% growth over the past year.
View the Zacks #1 Rank List
Image: Bigstock
Is it the Right Time to Hold TNDM Stock in Your Portfolio?
Key Takeaways
Tandem Diabetes Care, Inc. (TNDM - Free Report) is expanding its product roadmap with new integrations, broader device compatibility and next-generation closed-loop technology. The company's international expansion is driving sales growth and increasing direct-channel penetration across key markets. Strong cash reserves and the absence of short-term debt support its ongoing investments in growth. Yet, competitive pressure and supply constraints could weigh on growth.
In the past year, this Zacks Rank #3 (Hold) stock has risen 11.9% compared to the 7.6% growth of the industry. However, the S&P 500 composite has risen 21.2% during the same time period.
The renowned medical device company has a market capitalization of $1.10 billion. Tandem projects an estimated earnings growth rate of 74.4% for 2026, outpacing the industry’s 16.5% growth. TNDM’s earnings have surpassed estimates in each of the trailing four quarters, delivering an average surprise of 30.9%.
Let’s delve deeper.
Tailwinds for TNDM Stock
Product Roadmap Broadens Choice: Tandem’s platform strategy continues to add integrations and features that keep its installed base current while widening customer choice. In second-quarter 2026, the company submitted a 510(k) for Mobi tubeless and still targets a scaled launch in 2026, subject to FDA clearance. Dexcom G7 15-day compatibility is now available for Mobi and t:slim X2 in the United States, while t:slim X2 supports Abbott FreeStyle Libre 3 Plus in seven countries outside the United States. Tandem also received FDA approval of an IDE for its AIDANET fully closed-loop program and plans to begin a pivotal study later in 2026. These milestones extend the roadmap beyond current durable pumps and broaden potential competitive conversion opportunities.
Image Source: Zacks Investment Research
International Expansion Supports Mix: International markets remain less penetrated than the United States and provide room for adoption as Tandem expands direct commercialization. In second-quarter 2026, international sales rose 7% year over year to $75.3 million and pump shipments increased 19% to about 11,000. Direct-channel sales reached about 13% of international revenues compared with 4% a year earlier, despite roughly $3 million of distributor inventory buybacks and destocking tied to market transitions. Tandem launched direct operations in the United Kingdom, Switzerland and Austria, with France planned for the fourth quarter of 2026. The company also plans to introduce Mobi in more than 10 countries by year-end, adding another route to grow pump starts and recurring supplies.
Liquidity Supports Execution: Tandem ended second-quarter 2026 with $456 million of cash, cash equivalents and short-term investments and further reinforced its balance sheet by closing a 0.00% convertible debt offering due 2032. The company had no short-term debt at the end of the quarter. Net cash used in operating activities was $23.6 million for the first half of 2026, modestly better than $27.8 million a year earlier despite investment in commercial infrastructure and product development.
Challenges for TNDM Stock
Tough Competitive Pressure: Tandem operates in a fast-changing insulin delivery market where rivals can use broader distribution, pricing incentives and new device features to influence payer and patient choices. The company also states that adoption of GLP-1 drugs has likely weighed on the insulin therapy market since 2023. Its response depends on maintaining differentiation through Control-IQ+, sensor compatibility and new form factors. Tandem submitted Mobi tubeless for FDA review in second-quarter 2026, but clearance and launch execution are still required before it can participate directly in the faster-growing tubeless segment identified by management.
Reliance on Pump Platform Execution: Tandem depends on pump placements to expand its installed base and drive recurring supply demand, leaving results sensitive to product launches and component availability. In second-quarter 2026, the company shipped about 33,000 pumps worldwide, while a key infusion set supplier constrained supply sales and inventory. Management believes the second quarter carried the greatest impact, but the 10-Q states inventory constraints are expected to persist through 2026. AutoSoft Plus is intended to reduce demand for allocated infusion-set SKUs, and SteadiSet is planned for the first half of 2027.
TNDM Stock Consensus Trend
The Zacks Consensus Estimate for Tandem’s 2026 loss per share currently stands at 66 cents, indicating a year-over-year improvement of 74.4%.
The same for 2026 revenues is pegged at $1.07 billion. This suggests a 5.7% increase from the year-ago reported number.
Key Picks
Some better-ranked stocks in the broader medical space are Phibro Animal Health (PAHC - Free Report) , Abbott (ABT - Free Report) and Globus Medical (GMED - Free Report) .
Phibro Animal Health has an earnings yield of 9.3% compared with the industry’s 2.7% yield. Shares of the company have risen 2.8% against the industry’s 28.9% decline. PAHC’s earnings outpaced estimates in each of the trailing four quarters, the average surprise being 18.4%.
PAHC sports a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Abbott, carrying a Zacks Rank #2 (Buy), has an earnings yield of 5.6% compared with the industry’s 2.6% yield. Its earnings beat estimates in each of the trailing four quarters, the average surprise being 0.8%. ABT’s shares have plunged 25.7% compared with the industry’s 28.9% decline over the past year.
Globus Medical, carrying a Zacks Rank #2, has an earnings yield of 6.8% against the industry’s negative 1.7% yield. Its earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 27.9%. GMED’s shares have rallied 29.6% compared with the industry’s 7.6% growth over the past year.